Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The company is headquartered in Perth, Western Australia. The company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its prescription (Rx) business, including insomnia, autism and chronic non-cancer pain. Its lead product, Zenivol, is a cannabinoid-based medicine for the treatment of chronic insomnia. The company also provides formulations under the HOPE brand. The firm is engaged in human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the United States. The company is also focused on pre-clinical research examining the effects of cannabinoids in breast, brain and pancreatic cancer, as well as research and development of cannabinoids to treat diabetes-associated cognitive diseases. Its SprinjeneCBD toothpaste product is a hemp-derived, oral care product containing cannabinoids, based on the technology of blackseed oil.